---
title: "Wave Life Sciences Ltd. (WVE.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/WVE.US.md"
symbol: "WVE.US"
name: "Wave Life Sciences Ltd."
industry: "Pharmaceuticals"
datetime: "2026-04-15T13:34:03.003Z"
locales:
  - [en](https://longbridge.com/en/quote/WVE.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/WVE.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/WVE.US.md)
---

# Wave Life Sciences Ltd. (WVE.US)

## Company Overview

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [wavelifesciences.com](https://wavelifesciences.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-15T04:30:15.000Z

**Overall: D (0.68)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 135 / 187 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -60.55% |  |
| Net Profit YoY | -110.68% |  |
| P/B Ratio | 2.65 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1372765720.12 |  |
| Revenue | 42727000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -56.16% | E |
| Profit Margin | -478.33% | E |
| Gross Margin | -327.78% | E |
| Revenue YoY | -60.55% | E |
| Net Profit YoY | -110.68% | E |
| Total Assets YoY | 81.29% | A |
| Net Assets YoY | 142.07% | A |
| Cash Flow Margin | 91.74% | C |
| OCF YoY | -60.55% | E |
| Turnover | 0.09 | E |
| Gearing Ratio | 17.58% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Wave Life Sciences Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-60.55%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-110.68%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.65",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1372765720.12",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "42727000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-56.16%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-478.33%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-327.78%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-60.55%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-110.68%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "81.29%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "142.07%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "91.74%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-60.55%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.09",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "17.58%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -6.72 | 171/187 | - | - | - |
| PB | 2.65 | 106/187 | 19.09 | 8.25 | 5.46 |
| PS (TTM) | 32.13 | 133/187 | 25.13 | 13.34 | 10.34 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Eli Lilly (LLY.US) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 03 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 04 | AstraZeneca (AZN.US) | A | B | C | D | B | B |
| 05 | NOVARTIS AG (NVS.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-14T04:00:00.000Z

Total Analysts: **16**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 14 | 88% |
| Overweight | 2 | 13% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.39 |
| Highest Target | 52.00 |
| Lowest Target | 11.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/WVE.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/WVE.US/norm.md)
- [Related News](https://longbridge.com/en/quote/WVE.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/WVE.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**